GlassScriptPhysician profile
Aaron M Dickstein
NPI 1003059239
$5,644.86
in general payments reported to CMS, 2019-2025
24 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $169 · 2021: $416 · 2022: $487 · 2023: $1,095 · 2024: $1,268 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,670 · Gift: $40.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.82 |
| Gift | $40.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,347.82 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $897.19 | 2019-2025 | Xifaxan |
| Braintree Laboratories, INC. | $461.68 | 2021-2025 | Sutab, Suflave |
| Covidien LP | $410.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.27 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $305.30 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $301.16 | 2023-2025 | Voquezna |
| Genzyme Corporation | $296.75 | 2022-2025 | |
| Janssen Biotech, INC. | $258.06 | 2019-2024 | Tremfya, Stelara |
| Lilly USA, LLC | $193.00 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $151.69 | 2023-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $120.81 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $111.18 | 2021-2025 | Rebyota |
| Pfizer INC. | $85.03 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $75.65 | 2024-2025 | Vowst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $72.95 | 2022-2025 | Linzess |
| Madrigal Pharmaceuticals | $70.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Lucid Diagnostics INC. | $39.23 | 2024-2025 | |
| Redhill Biopharma INC. | $36.80 | 2021-2022 | |
| Organon LLC | $23.90 | 2024 | |
| Shire North American Group INC | $16.97 | 2019 | |
| Alfasigma USA, INC. | $16.67 | 2021 | |
| Henry Schein, INC. | $16.41 | 2024 | |
| Ucb, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Dickstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.